A Novel Method for Determination of Thromboembolic Stroke Origin
Part of paid clinical trials in Summit, New Jersey.
- Sponsor
- Atlantic Health System
- Study ID
- NCT06961604
- Phase
- EARLY_PHASE1
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Thromboembolic Stroke
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- NaF PET-CT — DRUGFollowing a non-cardiogenic thromboembolic stroke, patients will undergo NaF PET-CT imaging to identify the culprit plaque and any other vulnerable plaques at high risk for rupture
Study Details
Rupture of vulnerable carotid, vertebral, and intracranial arterial plaques results in thromboembolic stroke. Identification of these culprit lesions is an important component of post-stroke care. This study seeks to test the feasibility of NaF PET-CT to detect these plaques and alter patient care. Prior studies have shown a high degree of correlation between NaF PET+ lesions and high-risk plaque features on high resolution MRI, including mirocalcification, necrosis, and ulceration.
Key Dates
- Start date
- Jun 1, 2025
- Status verified
- May 2025
- Primary completion
- Jun 1, 2025
- Completion
- May 31, 2026
Study Design
- Enrollment
- 20 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- DIAGNOSTIC
Arms
- Experimental: Intervention - NaF PETIntervention/Experimental Arm - non-cardiogenic thromboembolic stroke patients to undergo NaF PET-CT
Primary Outcome Measure
Culprit lesion [ Time Frame: Within 14 days of the stroke ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Overlook Medical Center | Summit | New Jersey | 07901 | James Cassuto, MD, PhD (PRINCIPAL_INVESTIGATOR) |